ES2372203T3 - Dihidrochalcona similar a aspalatina y procedimiento de preparación. - Google Patents

Dihidrochalcona similar a aspalatina y procedimiento de preparación. Download PDF

Info

Publication number
ES2372203T3
ES2372203T3 ES07020728T ES07020728T ES2372203T3 ES 2372203 T3 ES2372203 T3 ES 2372203T3 ES 07020728 T ES07020728 T ES 07020728T ES 07020728 T ES07020728 T ES 07020728T ES 2372203 T3 ES2372203 T3 ES 2372203T3
Authority
ES
Spain
Prior art keywords
formula
rooibos
extract
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07020728T
Other languages
English (en)
Spanish (es)
Inventor
Bruno. Dr Frank
Wilfried. Prof. Dr Dimpfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kneipp Werke Kneipp Mittel Zentrale GmbH and Co KG
Original Assignee
Kneipp Werke Kneipp Mittel Zentrale GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38805677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2372203(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kneipp Werke Kneipp Mittel Zentrale GmbH and Co KG filed Critical Kneipp Werke Kneipp Mittel Zentrale GmbH and Co KG
Application granted granted Critical
Publication of ES2372203T3 publication Critical patent/ES2372203T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES07020728T 2007-10-23 2007-10-23 Dihidrochalcona similar a aspalatina y procedimiento de preparación. Active ES2372203T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07020728A EP2053050B1 (de) 2007-10-23 2007-10-23 Aspalathin-ähnliches Dihydrochalcon und Verfahren zur Herstellung

Publications (1)

Publication Number Publication Date
ES2372203T3 true ES2372203T3 (es) 2012-01-17

Family

ID=38805677

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07020728T Active ES2372203T3 (es) 2007-10-23 2007-10-23 Dihidrochalcona similar a aspalatina y procedimiento de preparación.
ES08801873.4T Active ES2373509T5 (es) 2007-10-23 2008-09-05 Dihidrochalcona similar a aspalatina, extractos de rooibos no fermentado y procedimiento de preparación

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08801873.4T Active ES2373509T5 (es) 2007-10-23 2008-09-05 Dihidrochalcona similar a aspalatina, extractos de rooibos no fermentado y procedimiento de preparación

Country Status (10)

Country Link
US (1) US20100222423A1 (enExample)
EP (2) EP2053050B1 (enExample)
JP (1) JP5527900B2 (enExample)
AT (2) ATE522524T1 (enExample)
DK (2) DK2053050T3 (enExample)
ES (2) ES2372203T3 (enExample)
HR (1) HRP20110890T4 (enExample)
PL (2) PL2053050T3 (enExample)
PT (2) PT2053050E (enExample)
WO (1) WO2009052895A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520913A (ja) 2007-03-12 2010-06-17 サズセ アーペーエス ルイボスの抗糖尿病性抽出物
JP6797408B2 (ja) 2014-11-06 2020-12-09 国立大学法人 長崎大学 新規アルツハイマー病治療薬
JP6735224B2 (ja) 2016-01-28 2020-08-05 花王株式会社 アストロサイトのグルコース代謝活性化剤
JP7244273B2 (ja) * 2018-12-27 2023-03-22 株式会社 伊藤園 ルイボス茶飲料の製造方法
CN109932448A (zh) * 2019-03-29 2019-06-25 完美（广东）日用品有限公司 一种线叶金雀花及其制品中有效成分的含量测定方法
CN115104730A (zh) * 2022-06-28 2022-09-27 北京姿美堂生物技术股份有限公司 一种改善睡眠的组合物、线叶金雀花-芦笋睡眠改善液、茶粉的制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2895298B2 (ja) * 1991-12-27 1999-05-24 株式会社ユニエ 活性酸素消去・除去剤
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
JPH11116429A (ja) † 1997-10-13 1999-04-27 Mikimoto Pharmaceut Co Ltd 化粧品原料および化粧品
JP2001316239A (ja) * 2000-05-10 2001-11-13 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
KR100421233B1 (ko) * 2001-09-10 2004-03-11 한국원자력연구소 식품, 의약품 및 화장품 제조용 천연물의 색도 개선 방법 및 이의 방법에 의해 색도가 개선된 천연물 추출물
ZA200303674B (en) * 2002-02-20 2005-04-26 Benedict Technology Holdings P Antioxidant composition.
JP4637491B2 (ja) * 2004-03-01 2011-02-23 株式会社東洋発酵 抗アレルギー用組成物
DE102004052800B4 (de) * 2004-10-30 2017-02-23 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Verbesserte Trägerformulierungen
DE102005004438B4 (de) * 2005-01-31 2007-12-20 Raps Gmbh & Co. Kg Rooibos-Extrakt mit erhöhtem Aspalathingehalt, Verfahren zur Herstellung eines solchen Rooibos-Extraktes und kosmetisches Mittel enthaltend einen solchen Rooibos-Extrakt
JP2007161661A (ja) * 2005-12-15 2007-06-28 Pola Chem Ind Inc アドバンスド・グリケーション・エンドプロダクツを分解するための化粧料とその製造法
JP2010520913A (ja) † 2007-03-12 2010-06-17 サズセ アーペーエス ルイボスの抗糖尿病性抽出物

Also Published As

Publication number Publication date
PL2069334T3 (pl) 2012-04-30
US20100222423A1 (en) 2010-09-02
PT2053050E (pt) 2011-12-09
ATE533763T1 (de) 2011-12-15
PL2069334T5 (pl) 2015-06-30
JP5527900B2 (ja) 2014-06-25
HRP20110890T4 (xx) 2015-02-27
EP2069334B1 (de) 2011-11-16
EP2069334B2 (de) 2014-11-05
EP2053050A1 (de) 2009-04-29
ATE522524T1 (de) 2011-09-15
PL2053050T3 (pl) 2012-01-31
PT2069334E (pt) 2011-12-30
ES2373509T5 (es) 2015-02-16
WO2009052895A1 (de) 2009-04-30
DK2069334T3 (da) 2012-01-23
ES2373509T3 (es) 2012-02-06
DK2053050T3 (da) 2011-11-21
DK2069334T4 (da) 2014-12-08
EP2053050B1 (de) 2011-08-31
EP2069334A1 (de) 2009-06-17
JP2011501755A (ja) 2011-01-13
HRP20110890T1 (hr) 2011-12-31

Similar Documents

Publication Publication Date Title
KR102163313B1 (ko) 체중 관리를 위한 조성물 및 방법
JP5226053B2 (ja) ベンジルイソキノリン誘導体またはビスベンジルイソキノリン誘導体を含有する向精神薬、鎮痛薬および／または抗炎症薬、ならびに健康食品
JP5654991B2 (ja) 認知症疾患の症状を改善するための種々の植物抽出物の組合せ
US20180193399A1 (en) Compound and method for treating spasms, inflammation and pain
JP6517206B2 (ja) 新規肺線維症治療剤、その調整方法
ES2372203T3 (es) Dihidrochalcona similar a aspalatina y procedimiento de preparación.
CN103059043A (zh) 伸筋草碱a-c、其制法和其药物组合物与用途
CN102695521A (zh) 植物提取物，含所述提取物的组合物，其提取方法及其用途
US6737085B2 (en) Apocynum venetum extract for use as antidepressant
KR100523562B1 (ko) 손바닥선인장 추출물 및 이로부터 분리된 화합물을함유하는 신경세포 보호용 조성물
EP2766019B1 (en) Anti-inflammatory compounds
JPWO2015076286A1 (ja) エフェドリンアルカロイド除去麻黄エキスと、その製法及び用途
JPH01226824A (ja) 尿素窒素代謝改善剤
KR20090015704A (ko) 현삼 추출물을 유효성분으로 함유하는 인지기능 장애 관련질환의 예방 및 치료용 조성물
CN107253960B (zh) 野八角倍半木脂素及其制备方法、应用和药物组合物
KR102661884B1 (ko) 해방풍 추출물 또는 이의 분획물을 유효성분으로 포함하는 경도인지장애 개선용 조성물
CN110433168B (zh) 山茱萸新苷在制备治疗阿尔茨海默症药物中的用途
KR20140058975A (ko) 항유방암 및 항자궁경부암 활성을 갖는 개똥쑥의 추출방법
CN106800508B (zh) 野八角中新苯甲酸衍生物及其制备方法、应用和药物组合物
JP5193871B2 (ja) エリトリン ムルング（Ｅｒｙｔｈｒｉｎｅ Ｍｕｌｕｎｇｕ）誘導体を含む医薬組成物及びその製造方法
JP2020124191A (ja) 二日酔い解消用の組成物およびその製造方法
KR100857924B1 (ko) 우묵사스레피 추출물을 함유하는 피부 미백 조성물
Gupta et al. Isolation and identification of L-Dopa in the seeds of Abrus precatorius
KR20250023030A (ko) 토후박 추출물을 포함하는 천포창 개선 또는 치료용 조성물
ES2361923T3 (es) Procedimiento para la preparación de un extracto medicinal que contiene hidroxiestilbeno.